Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects

Autor:	Elshad, Hasanov, Isabel, Pimentel, Mara, Cruellas, Mark A, Lewis, Eric, Jonasch, Judith, Balmaña
Rok vydání:	2022
Předmět:	von Hippel-Lindau Disease Drug Development Neoplastic Syndromes Hereditary Mutation Humans Genomics General Medicine
Zdroj:	American Society of Clinical Oncology Educational Book. :808-824
ISSN:	1548-8756 1548-8748
DOI:	10.1200/edbk_350232
Popis:	Advances in the genetic basis of different tumors have led to identification of tumor vulnerabilities that can be turn into targeted therapies. In this regard, PARP inhibitors cause synthetic lethality with tumors harboring BRCA1 or BRCA2 genetic alterations. On the other hand, tumors with microsatellite instability, either due to germline or sporadic alterations, are candidates for immune checkpoint inhibitors. Finally, patients with von Hippel-Lindau disease who carry a germline alteration in the VHL gene may benefit form belzutifan, a hypoxia-inducible factor 2 alpha inhibitor. Overall, research on the underlying pathological mechanisms of these tumors has provided new therapeutic opportunities that might be expanded to other sporadic tumors with similar biology.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75430d57d0bb7698ef1336aad258f47e https://doi.org/10.1200/edbk_350232 Zobrazit plný text záznamu